More recently, roles of the NAD+ preservation in the islet β-cell survival and of the CD38-cADPR signal system in insulin secretion (described in Sections 4 and 5) with Imeglimin ((6R)-N2,N2,6-Trimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine monohydrochloride) have been recognized.285) Imeglimin is the first in a new class of oral anti-Type 2 diabetes agent286) and is scheduled to be launched in 2021 in Japan for the first time in the world. The gene discussed is CD38; the disease is type 2 diabetes mellitus.